Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Single Dose Promising In Phase I Study

Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.

Johnson_and_Johnson — J&J is planning to include 60,000 volunteers in its Phase III trial, more than any of the other frontrunners.

As Johnson & Johnson begins Phase III trials of its COVID-19 vaccine candidate, it has also just released early data suggesting it is effective in generating an immune response in adults of aged 18-65 and over, with no worrying safety problems detected so far.

J&J’s candidate, JNJ-78436735 (also known as Ad26.COV2.S), is being developed primarily as a single vaccination, rather than in a ‘prime...